RIVASTIGMINE TARTRATE
Rivastigmine tartrate is an orally administered cholinesterase inhibitor used to treat mild to moderate dementia. It increases cholinergic neurotransmission. Side effects include GI upset, anorexia, dizziness, sweating, insomnia, and risk of bradyarrhythmias in sensitive individuals.
About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of Action
RIVASTIGMINE TARTRATE (ID 27385) engages in multi‑layer biochemical interactions affecting enzyme cascades, receptor‑regulated signalling, oxidative‑stress systems, mitochondrial respiration, ion‑channel dynamics, cytoskeletal mechanics and transcription‑factor pathway coordination. Molecular‑modelling parameters suggest potential interactions with catalytic centres, allosteric microdomains, transmembrane receptor helices, cofactor‑binding regions, and structural scaffolding proteins. These interactions enable modulation of phosphorylation cycles, second‑messenger amplification (Ca²⁺, cAMP, IP₃, DAG), ATP turnover, mitochondrial membrane potential and ROS balancing capacity.
Benefits and Applications
- Receptor‑ligand affinity mapping and molecular docking
- Enzyme‑kinetic pathway modelling and catalytic‑flux analysis
- Mitochondrial bioenergetics profiling and redox‑state research
- Multi‑omics studies (transcriptomics, metabolomics, proteomics)
- Cytoskeletal architecture analysis and membrane‑dynamics modelling
- Apoptosis, necroptosis, autophagy and ferroptosis pathway assays
- SAR and QSAR‑driven molecular optimisation
- Pharmacodynamic and mechanistic dose‑response modelling
Risks & Side Effects
- Oxidative imbalance and ROS escalation
- Mitochondrial overload or suppression of respiratory complexes
- Ion‑channel destabilisation (Na⁺/K⁺/Ca²⁺)
- Unintended receptor cross‑talk
- Cytoskeletal destabilisation
- Dose‑dependent cytotoxicity or programmed‑cell‑death activation
- Inflammatory transcriptional activation (NF‑κB, JNK, MAPK)
Datasheet
| Molecular Formula | C14H22N2O2·C4H6O6 |
|---|---|
| Molecular Weight | 400.4 g/mol |
| CAS Number | 129101-54-8 |
| Storage Condition | Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light. |
| Solubility | Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance. |
| Purity | Purity information is available upon request (COA). |
| Synonym | Rivastigmine tartrate; 129101-54-8; Rivastigmine Hydrogen Tartrate; Rivastigmine bitartrate; ENA 713 |
| IUPAC/Chemical Name | (2R,3R)-2,3-dihydroxybutanedioic acid;[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate |
| InChl Key | GWHQHAUAXRMMOT-MBANBULQSA-N |
| InChl Code | InChI=1S/C14H22N2O2.C4H6O6/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4;5-1(3(7)8)2(6)4(9)10/h7-11H,6H2,1-5H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-;1-,2-/m01/s1 |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
